Related Experiment Video
Updated: Jun 9, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Optimizing resection for "responding" hepatic metastases after neoadjuvant chemotherapy
Alan A Thomay1, Kevin P Charpentier
1Department of Surgery, The Alpert Medical School, Brown University, Rhode Island Hospital, Providence, Rhode Island, USA.
Abstract:
Fifty percent of patients with colorectal cancer will develop metastases at some time during their disease, with the liver being the most common site. Recent advances in the treatment of metastatic colorectal cancer have led to a change in treatment paradigm. What follows is a review of the surgical management of hepatic colorectal metastases responding to neoadjuvant chemotherapy. In addition, the complexity of treating patients with "disappearing" colorectal liver metastases is discussed.
